Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, randomized, active and vehicle controlled, Investigator blind, multi-centre study to evaluate the efficacy, safety and tolerability of topically applied tretinoin formulated with TPM as an anti-acne preparation in human subjects with acne vulgaris.

Trial Profile

A Phase II, randomized, active and vehicle controlled, Investigator blind, multi-centre study to evaluate the efficacy, safety and tolerability of topically applied tretinoin formulated with TPM as an anti-acne preparation in human subjects with acne vulgaris.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tretinoin (Primary)
  • Indications Acne vulgaris
  • Focus Therapeutic Use
  • Sponsors Phosphagenics

Most Recent Events

  • 19 Nov 2014 New source identified and integrated: Australian New Zealand Clinical Trials Registry record.
  • 08 Oct 2014 Status changed from active, no longer recruiting to completed, according to a Phosphagenics media release.
  • 07 Oct 2014 Primary endpoints (change in total acne lesion count, and success rate on the Investigators Global Assessment) have not been met, but the trial was not powered for significance, according to a Phosphagenics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top